Does Dr. AMRUT AMBARDEKAR have financial conflicts of interest?

Dr. AMRUT AMBARDEKAR (MD) has received a total of $504 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $504 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. AMRUT AMBARDEKAR?

According to CMS Open Payments data, Dr. AMRUT AMBARDEKAR received funding from VIFOR PHARMA ($200), ALNYLAM PHARMACEUTICALS ($177), and ASTRAZENECA PHARMACEUTICALS ($128).

Does Dr. AMRUT AMBARDEKAR receive research grants or speaking fees?

Dr. AMRUT AMBARDEKAR has received $504 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. AMRUT AMBARDEKAR

MDReal-Time Hydrated

Specialty: Internal Medicine, Advanced Heart Failure and Transplant Cardiology

Practice Location: AURORA, CO 80045

NPI Number: 1700975042

LIFETIME INDUSTRY VALUE

$504

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. AMBARDEKAR is a verified Internal Medicine, Advanced Heart Failure and Transplant Cardiology practitioner based in AURORA, CO.

Between 2021 and 2025, Dr. AMBARDEKAR had an overall industry promotional and research financial footprint of $504 as recorded in the federal CMS Open Payments database.

$504 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. AMBARDEKAR's primary funding source is VIFOR PHARMA, which accounts for $200 (representing 39.7% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

VIFOR PHARMA

Rank 1

$200

39.7%

ALNYLAM PHARMACEUTICALS

Rank 2

$177

35.1%

ASTRAZENECA PHARMACEUTICALS

Rank 3

$128

25.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.